Cosmos Health forecasts 2029 net income of $31 million

• Cosmos Health issued 2029 guidance for revenue of $200.6 million, gross profit of $71.2 million, adjusted EBITDA of $44.2 million.
• Net income is forecast at $31 million, with execution tied to a mix shift toward higher-margin proprietary products.
• Management expects gross margins above 70% across key brands, including Sky Premium Life, the 18 Series, C-Scrub.
• Contract manufacturing at Cana Laboratories is cited as a margin lever, with reported gross margins above 90% for third-party production.
• Outlook is supported by brands sold in more than 40 countries, targeting markets estimated at $946.3 billion in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.